Market closedNon-fractional
Fate Therapeutics/FATE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Fate Therapeutics
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Ticker
FATE
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
181
Website
www.fatetherapeutics.com
FATE Metrics
BasicAdvanced
$615M
Market cap
-
P/E ratio
-$1.92
EPS
1.90
Beta
-
Dividend rate
Price and volume
Market cap
$615M
Beta
1.9
Financial strength
Current ratio
8.693
Quick ratio
8.473
Long term debt to equity
22.451
Total debt to equity
23.954
Management effectiveness
Return on assets (TTM)
-20.84%
Return on equity (TTM)
-42.07%
Valuation
Price to revenue (TTM)
82.671
Price to book
1.44
Price to tangible book (TTM)
1.44
Price to free cash flow (TTM)
-3.831
Growth
Revenue change (TTM)
-95.27%
Earnings per share change (TTM)
-20.66%
3-year revenue growth (CAGR)
-45.52%
3-year earnings per share growth (CAGR)
-3.49%
What the Analysts think about FATE
Analyst Ratings
Majority rating from 19 analysts.
FATE Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.9M
18.75%
Net income
-$48M
8.84%
Profit margin
-2,526.31%
-8.34%
FATE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.54
-$0.46
-$0.45
-$0.47
-
Expected
-$0.59
-$0.57
-$0.52
-$0.49
-$0.48
Surprise
-8.22%
-19.28%
-13.90%
-3.83%
-
FATE News
AllArticlesVideos
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm
PRNewsWire·1 month ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fate Therapeutics stock?
Fate Therapeutics (FATE) has a market cap of $615M as of July 27, 2024.
What is the P/E ratio for Fate Therapeutics stock?
The price to earnings (P/E) ratio for Fate Therapeutics (FATE) stock is 0 as of July 27, 2024.
Does Fate Therapeutics stock pay dividends?
No, Fate Therapeutics (FATE) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Fate Therapeutics dividend payment date?
Fate Therapeutics (FATE) stock does not pay dividends to its shareholders.
What is the beta indicator for Fate Therapeutics?
Fate Therapeutics (FATE) has a beta rating of 1.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Fate Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.